Over the past ten years, relying on the core technology of targeted capture sequencing and project experience, iGeneTech has launched more than 20 predefined oncology-related products. These range from the most comprehensive tumor whole exome, large, medium and small panels of oncology-related genes, to products for detecting mutations in individual important genes, such as TP53, FLT3-ITD, and mutations in the kinase region of BCR-ABL1. Currently, a product matrix has been formed, covering the detection of various mutation types in pan-cancer, solid tumors and hematological malignancies.
Meanwhile, in 2024, iGeneTech also introduced a product matrix for nucleic acid extraction, including the Class I record-filing of nearly ten types of extraction kits for common samples such as FFPE samples, cell-free nucleic acids, and pathogenic microorganisms.
Over the past decade, iGeneTech has provided more than 4,000 customized panels for corporate customers. Its rich experience in design and synthesis, stable and excellent performance of the kits, and the accumulation of abundant database information have continuously propelled iGeneTech to meticulously refine its predefined products for various applications. At the same time, based on these predefined products, iGeneTech has also developed a variety of customized Plus products for numerous domestic and overseas customers.
Widely Applicable and Excellent in Performance
TargetSeq® NSCLC Panel V2 - It is designed for 23 genes clearly recommended in the NCCN Guidelines and other relevant guidelines, which are related to the treatment of non-small cell lung cancer (NSCLC). It includes the entire exonic regions of these 23 genes as well as the hot fusion regions related to BRAF, ALK, RET, ROS1, MET Exon 14 Skipping Mutation, etc. It can detect various mutation types such as mutations, fusions, copy number variations, and insertions/deletions all at once, providing references for clinical treatment decisions.
TargetSeq® Soild Tumor Mid Panel V2 - A streamlined multi-cancer detection panel that covers the coding regions of 124 genes, the fusion regions of 10 key genes, 19 microsatellite instability (MSI) loci, and 213 chemotherapy-related loci. It can evaluate the microsatellite instability status of tumors, assist in the selection of clinical chemotherapy regimens, and provide comprehensive and valuable reference information for targeted cancer therapy and immunotherapy.
TargetSeq® Pan-Cancer Panel - It covers 641 genes related to targeted drug use for solid tumors and tumor genetic susceptibility. Additionally, it includes 38 hot fusion intron regions and 15 classic microsatellite loci. It can detect mutation types like point mutations, fusions, copy number variations, and insertions/deletions all at once, and conduct analyses of tumor mutational burden (TMB) and microsatellite instability (MSI). It can provide references for targeted cancer therapy, immunotherapy, and the prediction of the risk of hereditary tumors.
TargetSeq® Solid Tumor Fusion RNA Panel - This product covers the coding regions of the transcripts of 298 common fusion master genes related to solid tumors and the UTR regions of some genes. It supports the detection of fusions, variations, and gene expression information at the RNA level, providing clinical references for tumor diagnosis and classification, prognosis assessment, and recurrence monitoring.
TargetSeq® Core Genes Fusion RNA Panel - Probes are designed for the coding regions of the transcripts of 90 common fusion master genes in tumors and the UTR regions of some genes. It supports the detection of fusions, variations, and gene expression information at the RNA level, providing clinical references for tumor diagnosis and classification, prognosis assessment, and recurrence monitoring.
TargetSeq® Hema Tumor Fusion RNA Panel - This product covers the transcripts of the master genes of 141 common fusion events in hematological malignancies, such as KMT2A, RARα, NUP98, etc. It can provide clinical references for the diagnosis and classification, prognosis assessment, and recurrence monitoring of hematological diseases.
Unique and Striving for Excellence
AIExome® Human Exome Panel V3 – Tumor Panel - On the basis of the core version of AIExome® V3, the probe coverage density of 641 tumor-related genes (especially mutation hotspots) is increased. Additionally, 38 intronic regions of hotspot fusion genes, 15 microsatellite instability regions, and parts of the HLA are added, comprehensively meeting the requirements of whole-exome sequencing in tumor application scenarios.
TargetSeq® HRD Panel - Developed by iGeneTech based on the genetic background and efficacy data of the Chinese population, this panel effectively covers approximately 37,000 SNP loci across the entire genome. It determines the HRD status of patients through the scoring of genomic instability indicators (LOH, TAI, and LST).
TargetSeq® HRR Panel - iGeneTech developed this panel by referring to the NCCN Guidelines, clinical trials of drugs such as olaparib, and reports in authoritative journals like The Lancet. It focuses on 39 core genes in the HRR pathway, including BRCA1, BRCA2, and ATM, and is used to detect various mutation types, such as point mutations, insertions/deletions, and amplifications.
TargetSeq® HRD & HRR Panel - This product can simultaneously detect gene mutations in the HRR pathway. Combining with iGeneTech's self-developed HRD algorithm, it calculates instability indicators (LOH, TAI, and LST) for scoring to determine the HRD status of patients. Moreover, in the final capture data, the effective depth ratio of HRR to HRD can reach 4:1. This not only significantly reduces the sequencing cost of co-detection but also provides a basis for clinically comprehensive and effective screening of patients who may benefit from platinum/PARP inhibitor drugs.
Focused and Pragmatically Innovative
MultipSeq® BRCA1/2 Research Assay V2 - This product covers the exonic regions of the BRCA1/2 genes and loci in important non - exonic regions from the ClinVar database. It can detect point mutations and insertions/deletions related to these genes, and is suitable for the diagnosis, screening, and risk assessment of hereditary breast cancer, ovarian cancer, etc.
MultipSeq® FLT3 - ITD Primer Pool - The FLT3 - ITD mutation is one of the common pathogenic mutations in AML and is of great significance in the prognosis of hematological malignancies and guiding targeted therapy. Based on multiplex amplicon sequencing technology and a unique primer design, the entire region from intron 13 to exon 15 is included in the target area. By random amplification, the detection sensitivity is improved to accurately detect known and unknown ITD mutations occurring in exons 14 - 15.
MultipSeq® TP53 Primer Pool - As an important tumor suppressor gene in the human body, TP53 can not only prevent the division of tumor cells and induce apoptosis of tumor cells but also repair damaged normal DNA. By detecting the TP53 genotype, the genetic status of individual tumors can be evaluated, guiding plans can be provided, and the probability of cancer occurrence can be reduced. Therefore, this product is designed for the CDS region of the TP53 gene. Based on multiplex amplicon sequencing technology, it can efficiently and conveniently detect TP53 gene mutations through NGS.
MultipSeq® BCR - ABL1 Primer Pool - Tyrosine kinase inhibitors (TKIs) have become an important part of the first - line treatment for CML. However, some patients still develop primary or secondary drug resistance, and mutations in the BCR - ABL1 kinase region are the main mechanism of resistance. Currently, guidelines such as ELN and NCCN recommend mutation detection when CML patients show sub - optimal efficacy or treatment failure. In response, iGeneTech focuses on the 709 - 1657 region of the fused ABL1 NM_005157.6. Based on multiplex amplicon sequencing technology, it can efficiently and sensitively detect variations in the BCR - ABL1 kinase region through NGS.
TargetSeq® Lymphoma SV Panel - In high - grade B - cell lymphomas, rearrangements between genes such as MYC, BCL2, or BCL6 and the super - enhancer (IGH) are relatively common. Although these structural variations do not form specific fusion proteins, the abnormal chromosomal structure leads to over - expression/amplification of proto - oncogenes, resulting in a special subgroup with high aggressiveness and poor prognosis. This product uses probe capture to replace the traditional FISH method, covering the IGH class - switch regions involved in common structural variations and densely covering the MTC regions of genes such as MYC, BCL2, and BCL6, providing a basis for clinical targeted molecular typing and prognosis detection.
Innovation and Excellence
Tumor-informed MRD Research Kit - Based on Tumor-informed assays, combined with the self-developed hybridization capture system and the synthesis of high-throughput MRD Panel, a complete set of MRD hybridization capture reagents including hybridization capture reagents, blocking sequences, and capture magnetic beads is launched. Combined with the free customized MRD Panel, it forms a cost-effective and highly stable MRD detection solution, promoting the popularization of the clinical application of MRD detection.
TargetSeq® Pan-Cancer DNA+RNA Research Assay - In response to the demand for dual detection of DNA and RNA in solid tumors, it is comprehensively equipped with DNA and RNA sample library preparation reagents, hybridization capture reagents, and pan-cancer DNA+RNA probes. It can detect mutation types such as mutations, copy number amplifications, insertions/deletions, and fusions at the DNA level. At the same time, it can conduct auxiliary verification of fusion mutations and exon skipping at the RNA level. Through the dual detection of DNA and RNA, it helps with accurate fusion detection, supports clinical decision-making, and benefits patients.
Over the past decade, iGeneTech has continuously strengthened and innovated in the gene capture industry, paid attention to the cutting-edge trends in the field of tumor treatment, and constantly optimized and upgraded its products.
In the future, iGeneTech will also uphold its original aspiration, strive forward with determination, invest more resources in research and development innovation, enable cutting-edge technologies to be applied clinically more quickly, and bring more high-quality and personalized services to gene capture globally.
CN
